SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0000950170-23-008459
Filing Date
2023-03-16
Accepted
2023-03-16 16:11:10
Documents
14
Period of Report
2023-03-16
Items
Item 2.02: Results of Operations and Financial Condition
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K trvi-20230316.htm   iXBRL 8-K 67728
2 EX-99.1 trvi-ex99_1.htm EX-99 168529
3 GRAPHIC img251553556_0.jpg GRAPHIC 29443
  Complete submission text file 0000950170-23-008459.txt   410922

Data Files

Seq Description Document Type Size
4 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT trvi-20230316.xsd EX-101.SCH 2497
5 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT trvi-20230316_lab.xml EX-101.LAB 14264
6 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT trvi-20230316_pre.xml EX-101.PRE 11459
8 EXTRACTED XBRL INSTANCE DOCUMENT trvi-20230316_htm.xml XML 4888
Mailing Address 195 CHURCH STREET 14TH FLOOR NEW HAVEN CT 06510
Business Address 195 CHURCH STREET 14TH FLOOR NEW HAVEN CT 06510 203-304-2499
Trevi Therapeutics, Inc. (Filer) CIK: 0001563880 (see all company filings)

IRS No.: 450834299 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-38886 | Film No.: 23738888
SIC: 2834 Pharmaceutical Preparations